prazosin has been researched along with Diabetes Mellitus, Type 2 in 15 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the effectiveness and the safety of prazosin osmotic tablet treatment in non-insulin-dependent diabetic patients with mild to moderate arterial hypertension." | 9.09 | [Efficacy of and tolerance to prolonged release prazosin in patients with hypertension and non-insulin dependent diabetes]. ( Bernaud, C; Giacomino, A; Girerd, X; Hanon, O; Troy, S; Weber, S, 2000) |
| "The effects of the alpha-1-adrenergic blocker terazosin on blood pressure and fasting and postprandial glucose and lipid metabolism were assessed in type 2 diabetic patients with hypertension." | 9.09 | Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension. ( Ferrara, LA; Imperatore, G; Iovine, C; Pasanisi, F; Vaccaro, O, 1999) |
| "The effects of prazosin treatment on blood pressure and diabetic control were assessed in 22 patients with stable non-insulin-dependent diabetes mellitus and hypertension." | 7.67 | Effects of prazosin on blood pressure and diabetic control in patients with type II diabetes mellitus and mild essential hypertension. ( Levy, P, 1989) |
| "Doxazosin therapy was associated with opposite patterns of changes in fasting glucose, lipids and lipoproteins but only for serum triglyceride was difference between treatments significant." | 6.67 | Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. ( Elkeles, RS; Feher, MD; Gelding, S; Henderson, AD; Poulter, C; Richmond, W; Sever, PS; Wadsworth, J, 1990) |
| "Doxazosin therapy was associated with a trend toward correcting the disturbances of lipoprotein metabolism characteristic of NIDDM." | 6.38 | Doxazosin therapy in the treatment of diabetic hypertension. ( Feher, MD, 1991) |
| "The aim of this study was to evaluate the effectiveness and the safety of prazosin osmotic tablet treatment in non-insulin-dependent diabetic patients with mild to moderate arterial hypertension." | 5.09 | [Efficacy of and tolerance to prolonged release prazosin in patients with hypertension and non-insulin dependent diabetes]. ( Bernaud, C; Giacomino, A; Girerd, X; Hanon, O; Troy, S; Weber, S, 2000) |
| "The effects of the alpha-1-adrenergic blocker terazosin on blood pressure and fasting and postprandial glucose and lipid metabolism were assessed in type 2 diabetic patients with hypertension." | 5.09 | Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension. ( Ferrara, LA; Imperatore, G; Iovine, C; Pasanisi, F; Vaccaro, O, 1999) |
| " In this article, doxazosin is reviewed for its efficacy in the treatment of severe essential hypertension and specific complications or conditions of mild or moderate essential hypertension, namely, left ventricular hypertrophy, hyperlipidemia, noninsulin-dependent diabetes mellitus, renal insufficiency, pheochromocytoma, chronic obstructive pulmonary disease, peripheral vascular disease, and smoking." | 4.78 | Efficacy of doxazosin in specific hypertensive patient groups. ( Taylor, SH, 1991) |
| " The effect of a 2-week treatment with nifedipine, captopril and prazosin upon glycaemia, serum insulin (IRI) and C-peptide (CP) following oral and intravenous glucose load were investigated in three groups, each including 10 non-diabetic patients with essential hypertension (h) and 10 hypertensive type 2 (non-insulin-dependent) diabetics (h + d), aged 32-63 years." | 3.69 | Effect of nifedipine, captopril and prazosin on secretory function of pancreatic beta-cells in hypertensive patients with type-2 (non-insulin-dependent) diabetes and in hypertensive non-diabetics. ( Czyzyk, A; Jasik, M; Kasperska-Dworak, A, 1996) |
| "The effects of prazosin treatment on blood pressure and diabetic control were assessed in 22 patients with stable non-insulin-dependent diabetes mellitus and hypertension." | 3.67 | Effects of prazosin on blood pressure and diabetic control in patients with type II diabetes mellitus and mild essential hypertension. ( Levy, P, 1989) |
| "CARDIOVASCULAR RISK OF LEFT VENTRICULAR HYPERTROPHY: Because of the rhythmic, mechanical and ischemic risk related to it, the left ventricular hypertrophy (LVH) is considered to be a major independent risk factor for cardiovascular disease which should be screened for and treated early." | 2.70 | [Management of hypertensive patients with left ventricular hypertrophy]. ( Ambrosioni, E, 2002) |
| "Doxazosin therapy was associated with opposite patterns of changes in fasting glucose, lipids and lipoproteins but only for serum triglyceride was difference between treatments significant." | 2.67 | Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. ( Elkeles, RS; Feher, MD; Gelding, S; Henderson, AD; Poulter, C; Richmond, W; Sever, PS; Wadsworth, J, 1990) |
| "Doxazosin therapy was associated with a trend toward correcting the disturbances of lipoprotein metabolism characteristic of NIDDM." | 2.38 | Doxazosin therapy in the treatment of diabetic hypertension. ( Feher, MD, 1991) |
| "Hearts from animal models of type 2 diabetes present with abnormal contractility patterns." | 1.32 | A role for the alpha1-adrenergic signalling pathway in the response of papillary muscles from type 2 diabetic hearts to anoxia-reoxygenation. ( Huisamen, B; Lochner, A; Upton, J, 2004) |
| "Systemic hypertension is common in individuals with non-insulin-dependent diabetes (NIDD) and, in this population, markedly increases the risk for cardiovascular complications." | 1.31 | NaCl-induced hypertensive rat model of non-insulin-dependent diabetes: role of sympathetic modulation. ( Mozaffari, MS; Patel, C; Schaffer, SW; Warren, BK, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 8 (53.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, CS | 1 |
| Sung, SF | 1 |
| Tong, SH | 1 |
| Ong, CT | 1 |
| Ambrosioni, E | 1 |
| Hanon, O | 1 |
| Giacomino, A | 1 |
| Troy, S | 1 |
| Bernaud, C | 1 |
| Girerd, X | 1 |
| Weber, S | 1 |
| Huisamen, B | 1 |
| Upton, J | 1 |
| Lochner, A | 1 |
| Jasik, M | 1 |
| Kasperska-Dworak, A | 1 |
| Czyzyk, A | 1 |
| Pasanisi, F | 1 |
| Imperatore, G | 1 |
| Vaccaro, O | 1 |
| Iovine, C | 1 |
| Ferrara, LA | 1 |
| Mozaffari, MS | 1 |
| Patel, C | 1 |
| Warren, BK | 1 |
| Schaffer, SW | 1 |
| Bodansky, HJ | 1 |
| Maruyama, H | 1 |
| Saruta, T | 1 |
| Itoh, H | 1 |
| Koyama, K | 1 |
| Kido, K | 1 |
| Itoh, K | 1 |
| Takei, I | 1 |
| Kataoka, K | 1 |
| Taylor, SH | 1 |
| Nosadini, R | 1 |
| Crepaldi, G | 2 |
| D'Angelo, A | 2 |
| Feher, MD | 2 |
| Henderson, AD | 1 |
| Wadsworth, J | 1 |
| Poulter, C | 1 |
| Gelding, S | 1 |
| Richmond, W | 1 |
| Sever, PS | 1 |
| Elkeles, RS | 1 |
| Castrignano, R | 1 |
| Pati, T | 1 |
| Al Awady, M | 1 |
| Tronca, R | 1 |
| Levy, P | 1 |
2 reviews available for prazosin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Efficacy of doxazosin in specific hypertensive patient groups.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Cardiomegaly; Diabetes Mellitus, Type 2; Doxazosin | 1991 |
Doxazosin therapy in the treatment of diabetic hypertension.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Doxazosin; Humans; Hypertension; Lipids; Lipopro | 1991 |
4 trials available for prazosin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
[Management of hypertensive patients with left ventricular hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2002 |
[Efficacy of and tolerance to prolonged release prazosin in patients with hypertension and non-insulin dependent diabetes].
Topics: Aged; Antihypertensive Agents; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Angi | 2000 |
Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Area Under Curve; Blood Glucose; Choleste | 1999 |
Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
Topics: Adrenergic alpha-Antagonists; Aged; Atenolol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 1990 |
9 other studies available for prazosin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulc | 2012 |
A role for the alpha1-adrenergic signalling pathway in the response of papillary muscles from type 2 diabetic hearts to anoxia-reoxygenation.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Biomarkers; Blood Glucose; Diabete | 2004 |
Effect of nifedipine, captopril and prazosin on secretory function of pancreatic beta-cells in hypertensive patients with type-2 (non-insulin-dependent) diabetes and in hypertensive non-diabetics.
Topics: Adult; Antihypertensive Agents; Blood Glucose; C-Peptide; Calcium Channel Blockers; Captopril; Diabe | 1996 |
NaCl-induced hypertensive rat model of non-insulin-dependent diabetes: role of sympathetic modulation.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agon | 2000 |
Doxazosin: alternative antihypertensive treatment.
Topics: Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Doxazosin; Female; Humans; Hyper | 1992 |
Effect of alpha-adrenergic blockade on blood pressure, glucose, and lipid metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug E | 1991 |
Diabetes mellitus and hypertension: a physiologic basis for a rational therapeutic approach.
Topics: Antihypertensive Agents; Biological Transport; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 1991 |
A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
Effects of prazosin on blood pressure and diabetic control in patients with type II diabetes mellitus and mild essential hypertension.
Topics: Adult; Aged; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucose; Heart Rate; Humans; Hyperte | 1989 |